Status:
RECRUITING
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
Lead Sponsor:
Renata PLC
Conditions:
Primary Immune Thrombocytopenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
This will be a double-blind, placebo-control, randomized clinical trial conducted in the Department of Hematology, DMCH for one year. This study will help to establish the role of eltrombopag as a fir...
Detailed Description
Study procedure After meeting inclusion and exclusion criteria patients will be thoroughly informed about the study, used drugs, randomization, risk and benefits, follow up. If they agree to participa...
Eligibility Criteria
Inclusion
- Patients with newly diagnosed ITP
- Platelet Count ≤ 30x109/L
- Age between 18 to 70 years.
Exclusion
- Persistent or chronic ITP
- Pregnant women
- Secondary ITP- ITP due to SLE, Anti-phospholipid syndrome, Evans syndrome, HCV or H Pylori associated ITP.
- History of vaccination, recent viral infection, fever
- Evan's Syndrome
- Known case of chronic renal failure or liver diseases
- Grade 3 or 4 bleeding at presentation.
Key Trial Info
Start Date :
February 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06531018
Start Date
February 7 2025
End Date
December 31 2025
Last Update
February 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dhaka Medical College Hospital
Dhaka, Bangladesh, 1000